Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

438
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
438
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

438
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
438
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

96
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
96
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

179
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
179
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

490
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
490
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

458
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
458

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Decision and Cost-Effectiveness Analyses Complement Results From Randomized Clinical Trials.

JAMA·2026
Same author

Can artificial intelligence fulfill its potential to improve health and reduce costs?

Endoscopy·2026
Same author

We Care, and We Will Listen.

Primary care·2026
Same author

Social needs screening in hepatology clinic: a qualitative study of patient experience.

BMC gastroenterology·2026
Same author

Interventions for Increasing Colorectal Cancer Screening Uptake: A Systematic Review and Network Meta-Analysis.

Gastroenterology·2026
Same author

Mentorship in Gastroenterology - The Final Lesson.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026

Related Experiment Video

Updated: Jul 11, 2025

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring
06:46

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring

Published on: December 14, 2020

2.9K

Adverse Risks Associated With Proton Pump Inhibitors: A Systematic Review.

Joel J Heidelbaugh1, Kathleen L Goldberg2, John M Inadomi3

  • 1Dr. Heidelbaugh serves as Clinical Associate Professor in the Department of Family Medicine at the University of Michigan in Ann Arbor, Michigan.

Gastroenterology & Hepatology
|November 15, 2023
PubMed
Summary
This summary is machine-generated.

Proton pump inhibitors (PPIs) are widely used for upper gastrointestinal issues. This review highlights potential risks of PPI therapy, including infections, fractures, and nutrient deficiencies, recommending cautious use.

Keywords:
Proton pump inhibitorsoverutilizationrisk

More Related Videos

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

6.7K
Author Spotlight: Point-of-Care Ultrasound for Gastric Content Assessment and Risk Stratification in Perioperative Care
05:50

Author Spotlight: Point-of-Care Ultrasound for Gastric Content Assessment and Risk Stratification in Perioperative Care

Published on: September 22, 2023

2.9K

Related Experiment Videos

Last Updated: Jul 11, 2025

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring
06:46

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring

Published on: December 14, 2020

2.9K
The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

6.7K
Author Spotlight: Point-of-Care Ultrasound for Gastric Content Assessment and Risk Stratification in Perioperative Care
05:50

Author Spotlight: Point-of-Care Ultrasound for Gastric Content Assessment and Risk Stratification in Perioperative Care

Published on: September 22, 2023

2.9K

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Internal Medicine

Background:

  • Proton pump inhibitors (PPIs) are frequently prescribed for upper gastrointestinal disorders.
  • They represent a significant portion of both prescription and over-the-counter drug sales.

Purpose of the Study:

  • To systematically review the literature for rigorous studies linking PPI therapy to adverse events.
  • To evaluate the potential risks associated with both short-term and long-term PPI use.

Main Methods:

  • A systematic literature review was performed using the MEDLINE database.
  • The review focused on identifying high-quality studies examining PPI-associated adverse events.

Main Results:

  • Emerging evidence links PPI therapy to increased risks of *Clostridium difficile*-associated diarrhea.
  • Potential risks include community-acquired pneumonia, osteoporotic fractures, and vitamin B12 deficiency.
  • PPIs may also inhibit the effectiveness of antiplatelet therapies.

Conclusions:

  • Clinicians should regularly reassess the ongoing need for PPI therapy in patients.
  • Utilizing the lowest effective PPI dosage is recommended to minimize potential adverse events.